Table 3.

Association between TCF7L2 SNP (rs 12255372) and prostate cancer risk by clinical characteristics^*

Gleason score	Controls (n=540)		Cases: Gleason 2-6, 7=3+4 (n=503)						Cases: Gleason 7=4+3, 8-10 (n=76)
Genotype	n	%	n	%	OR1	95% CI	OR2	95% CI	n	%	OR1	95% CI	OR2	95% CI
GG	271	50.2%	270	53.7%	1.00	ref	1.00	ref	36	47.4%	1.00	ref	1.00	ref
GT	225	41.7%	199	39.6%	1.01	0.81-1.22	1.07	0.86-1.34	33	43.4%	0.99	0.68-1.45	1.03	0.70-1.51
TT	44	8.1%	34	6.8%	0.88	0.65-1.20	0.79	0.56-1.11	7	9.2%	1.10	0.63-1.92	1.06	0.60-1.87
Stage of cancer	Controls (n=540)		Cases: Local (n=422)						Cases: Regional or distant (n=154)
Genotype	n	%	n	%	OR1	95% CI	OR2	95% CI	n	%	OR1	95% CI	OR2	95% CI
GG	271	50.2%	224	53.1%	1.00	ref	1.00	ref	78	50.6%	1.00	ref	1.00	ref
GT	225	41.7%	175	41.5%	1.11	0.89-1.39	1.19	0.94-1.51	59	38.3%	0.85	0.64-1.12	0.90	0.68-1.21
TT	44	8.1%	23	5.5%	0.75	0.53-1.07	0.69	0.47-1.01	17	11.0%	1.26	0.85-1.86	1.15	0.76-1.73
Disease aggressiveness†	Controls (n=540)		Cases: Less aggressive (n=379)						Cases: More aggressive (n=203)
Genotype	n	%	n	%	OR1	95% CI	OR2	95% CI	n	%	OR1	95% CI	OR2	95% CI
GG	271	50.2%	205	54.1%	1.00	ref	1.00	ref	101	49.8%	1.00	ref	1.00	ref
GT	225	41.7%	151	39.8%	1.04	0.83-1.30	1.12	0.88-1.42	84	41.4%	0.97	0.75-1.25	1.03	0.79-1.35
TT	44	8.1%	23	6.1%	0.82	0.58-1.16	0.74	0.51-1.07	18	8.9%	1.06	0.73-1.56	1.03	0.69-1.53

^*15 cases and 8 controls have missing data for the TCF7L2 SNP (rs 12255372).

^†Less aggressive prostate cancer includes Gleason scores 2-6 or 7 (3+4) and local stage and PSA <20 ng/ml at diagnosis; More aggressive prostate cancer includes Gleason Scores 7 (4+3) or 8-10 or regional or distant cancer stage or a serum PSA ≥20 ng/ml at diagnosis.

¹OR - model is adjusted for age.

²OR - model is adjusted for age, first-degree family history of prostate cancer, prostate cancer screening history, and history of diabetes.

Abbreviations: OR - odds ratio; CI - confidence interval.